Arizona: 10:15 am, PX-SP-03-249/SC-RB-01-149J
Eau Claire: 12:15 pm, 1-1603 Amalia Conf Rm
Rochester: 12:15 pm, Geffen Aud/Fr M17
Florida: 1:15 pm, JA-CA-01-1107

Visiting Faculty
Anthony Lang, M.D.
Toronto Western Hospital
"Progressive Supranuclear Palsy and Corticobasal Degeneration"

Learning objectives:
Identify Tau and tauopathies
Identify the different pathologies and clinical phenotypes
Recognize the problems with diagnostic accuracy
Review the new diagnostic criteria
Recognize proposed mechanisms of neurodegeneration/pathogenesis
Recognize potential future approaches to therapeutics

The presenter (and/or spouse/partner) has the following relevant financial relationships to disclose:
Consultant - Abbvie, Acorda, Avanir Pharmaceuticals, Biogen, Bristol Myers Squibb, Sun Pharma, Cipla, Intekrin, and Merck
Grant/Research Support - Brain Canada, Canadian Journal Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, National Parkinson Foundation, Parkinson Society Canada, and W. Garfield Weston Foundation
Honoraria - Sun Pharma, Medichem, Medtronic, Teva, UCB, AbbVie and Sunovion
The presenter intends to discuss off-label/investigative uses of the following commercial products/devices:
Manufacturers/Providers - Biogen, BMS, AbbVie; Products/Devices - tau monoclonal antibodies